Trial Profile

Phase II Trial, Multicenter, First Line Paclitaxel-Avelumab Treatment for Inoperable Angiosarcoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 17 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avelumab (Primary) ; Paclitaxel (Primary)
Indications Haemangiosarcoma
Focus Therapeutic Use
Acronyms ASAP

Most Recent Events

04 Jun 2024 Results(n=32) assessing the efficacy and safety of Avelumab when given in combination with paclitaxel as a first line treatment for the patients with inoperable angiosarcoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
10 Jul 2018 Status changed from not yet recruiting to recruiting.
04 May 2018 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com